Drug Trial Radar · NCT02233647
Phendimetrazine and Cocaine
Last checked: Nov 20, 2026Latest source record: Sep 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Sep 2014
Primary completion
Dec 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- William StoopsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Sep 8, 2014
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will determine the safety and tolerability of phendimetrazine (Bontril®) as a pharmacotherapy for cocaine use disorder. A rigorous, inpatient human laboratory study will be conducted in which the subjective and physiological effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.
Conditions
- Cocaine Use Disorder
Interventions
CocaineDrug
The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
PlaceboDrug
The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Systolic PressureTime frame: This measure was completed at 15 minute intervals after sampling each cocaine dose under both phendimetrazine and placebo maintenance conditions.
- Peak Diastolic PressureTime frame: This measure was completed at 15 minute intervals after sampling each cocaine dose under both phendimetrazine and placebo maintenance conditions.
- Peak Heart RateTime frame: This measure was completed at 15 minute intervals after sampling each cocaine dose under both phendimetrazine and placebo maintenance conditions.
- Peak TemperatureTime frame: This measure was completed at 15 minute intervals after sampling each cocaine dose under both phendimetrazine and placebo maintenance conditions.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Kentucky Laboratory of Human Behavioral Pharmacology
Lexington, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.